

SWIXX APPOINTS MAREK VASICEK, MD, CHIEF OPERATING OFFICER RUSSIA / EURASIA AND R.O.W. (REST OF WORLD) EXPANSION

SWIXX ANNOUNCEMENT NO. 53

May 8th, 2023

Baar, Switzerland – Swixx BioPharma AG of Baar, Switzerland announces that Dr. Marek Vasicek will be joining our Executive Management Team as Chief Operating Officer Russia/ Eurasia and R.O.W. (Rest of World) Expansion as of May 8th, 2023. Among the key responsibilities of the newly-created COO role for non-CEE / Greece territories will be not only the coordination of our relationship with existing and new Partners in Russia/Eurasia, but also critical support to our Corporate Development and M&A Team in our efforts to enter new regions of “Rest of World” (R.O.W. or non-core countries beyond US/Canada, W. Europe, India, Japan, China, Korea, ANZUS).

At the same time, Dr. Dezso Martha will continue his successful leadership as Swixx COO in CEE + Greece markets and as the leader of HQ Commercial Team & Alliance Management. Whenever Partners are common to both regions, Dezso will retain ultimate Alliance Management responsibility, working closely with Marek who will assist in partnership management for all joint clients.

Marek has spent the last 23 years at Bristol-Myers Squibb (BMS) in various senior commercial roles in a variety of geographies. Most recently, Marek had been working as Transition Lead CEE and Interim General Manager Australia. Prior to that, he served as the General Manager BMS Russia, growing business from \$40M in 2016 to \$ 400M in 2021, launching immuno-oncology portfolio, establishing BMS as Oncology Leader (with 3 products in general Top 10) and integrating BMS and Celgene organizations after Celgene’s acquisition by BMS. Some of his other recent assignments in BMS included the positions of Strategy & Operations Director for CEE, Turkey, Greece & Israel, Interim General Manager China & Hong Kong and International Markets Commercialization Lead. Earlier in his BMS career, Marek led BMS’s EMEA Marketing Strategy for Abilify and served as General Manager Czech Republic. In addition, he served in Russia as BMS’s Director Commercialization, responsible for the overall portfolio commercialization and Alliance management in Diabetology with AstraZeneca and Cardiovascular with Pfizer.

Prior to working at BMS, Marek spent 6 years at Novartis Czech Republic and Slovakia in a series of positions with increasing responsibility including Business Unit Head Oncology and Marketing Manager Pharma.

Marek holds a doctorate from the 1st Medical Faculty of Charles University in Prague, an MBA from Manchester Metropolitan University and a GM Program Certificate from INSEAD. Through his career and as a working physician Marek has built-up substantial commercial expertise in multiple therapeutic areas including oncology, hematology, immunology, diabetes, cardiovascular and CNS. In addition to his native Czech language and excellent English, Marek speaks fluent Russian.

“I am convinced that Marek’s multiregional experience in various positions, his proven ability to manage across varied culture and across varied therapeutic areas and alliance functions, combined with his personal drive will accelerate our company’s development in new regions of the globe in the years ahead. We all warmly welcome Marek to Swixx,” commented Swixx’s CEO Jean-Michel Lespinasse.

About Swixx BioPharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, Russia and several Eurasian countries including Belarus, Kazakhstan, Moldova and Uzbekistan. With over 1200 employees and sales which exceeded 700M Euros in 2022, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma in the Central, Eastern and Southeastern regions of Europe. The company has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com

Contact: Vedrana Sokac Brataljenovic, Public Affairs Director, Swixx BioPharma AG
vedrana.sokac@swixxbiopharma.com Tel: +385 1 425 6086